Indeed, WT1 measurement by PCR has been proposed for monitoring minimal residual diseases in AML patients after allogeneic HSCT because WT1 levels strongly correlate with chimerism and disease relapse [21,22,23,24]. Here, WT1 is linked to acute myeloid leukemia.